The U.S. Food and Drug Administration (FDA) has approved a new coronavirus test that will accelerate patient testing tenfold compared to testing using MagNA Pure 24 and LightCycler 480.
The test was developed by Roche Holding AG and is designed for cobas 6800/8800 systems manufactured by this Swiss company. The 8800 system, when used, allows testing up to 4128 patients per day, and 6800 – up to 1440 patients. For the test, a sample of saliva or mucus is used, and the result becomes known within four hours. The test is already available in Europe. Testing is critical to preventing the spread of COVID-19 because it can detect infected people even if they do not experience many symptoms. This can potentially reduce the total number of infections and gain the time needed to create the best drugs and vaccines. It remains to add that there are 695 cobas 6800 systems and 132 cobas 8800 systems installed worldwide.